| Ytd | 32.81% | |
| 1y | 4.19% |
| Open | 11.98 | Prev Close | 11.24 | Low | 11.47 | High | 12.08 | Mkt Cap | 1.34B |
| Vol | 4.74M | Avg Vol | 5.69M | EPS | -3.36 | P/E | -3.55 | Forward P/E | -8.25 |
| Beta | 1.77 | Short Ratio | 7.30 | Inst. Own | 76.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 13.65 | 200-d Avg | 13.01 | 1yr Est | 26.17 |
CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration reven
Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average reco
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le
Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASD
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a
Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha
Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral a
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progr
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le
It might pull it off, provided several things fall right in place.
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipel
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once aga
U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a
There could be additional catalysts for this drugmaker over the next year.
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The
Top Wall Street analysts updated their ratings on top companies. For full list of changes, including
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018